Clinical validation of the Dry Blood Spot (DBS) method for risperidone, aripiprazole, pipamperone and its major metabolites

Completed

• Conditions: nvt; 10013511

• Registration Number: NL-OMON45799
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 120

Inclusion Criteria

In order to be eligible to participate in this study, a subject must meet all of the following criteria:
- using either aripiprazole, risperidone, paliperidone or pipamperone
- 18 years or older

Exclusion Criteria

nvt

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>the main study parameter is the agreement between antipsychotic drug plasma<br /><br>levels of blood collected by venipuncture or DBS, both measured by<br /><br>ultra-performance liquid chromatography tandem mass-spectrometry (UHPLC-MS/MS)<br /><br>. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Covariates influencing through levels</p><br>